drugset / Trial / NCT04924374
Microbiota Transplant in Advanced Lung Cancer Treated With Immunotherapy
Completed
25 enrolled
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
RandomizedParallel-groupOpen-labelTreatment
Summary
The gut microbiota can modulate the effectiveness of cancer therapies, especially immunotherapy. Manipulating the microbial populations in patients with advanced lung cancer through fecal microbiota transplantation from healthy individuals or from long-term survivors to advanced lung cancer will enhance the efficacy of immunotherapy.
Timeline
- Start
- 2021-04-23
- Primary completion
- 2023-11-15
- Completion
- 2023-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Atezolizumab | Monoclonal antibody | — | — |
| Comparator | Nivolizumab | Unknown | — | — |
| Comparator | Pembrolizumab | Monoclonal antibody | — | — |